CPC C07K 16/18 (2013.01) [A61K 31/704 (2013.01); A61K 38/191 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/525 (2013.01); C07K 14/56 (2013.01); C07K 16/2815 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)] | 13 Claims |
1. A composition comprising a chimeric protein consisting of:
(a) one or more modified signaling agents, wherein at least one signaling agent is a human interferon alpha 2 (IFNα2) comprising an amino acid sequence having at least 98% identity with a sequence selected from SEQ ID NO: 1 or 2 and having one or more mutations at one or more amino acid positions 144-154;
(b) one or more targeting moieties, wherein at least one targeting moiety comprises a single-domain antibody recognition domain which specifically binds to non-cellular tenascin-CA1 and,
wherein the one or more mutations confer reduced affinity or activity to IFNα2 that is restorable by attachment to the one or more targeting moieties,
wherein at least one targeting moiety and signaling agent are connected with one or more flexible linkers.
|